Evidence map›Paper›PMID 26758692›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016

Leveraging Optogenetic-Based Neurovascular Circuit Characterization for Repair.

Elena Ivanova, Christopher W Yee, Botir T Sagdullaev

Open access · bronzeAbstract readReview
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Selective Manipulation of Neural Circuits.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016
    Review
  6. Neural Circuits Catch Fire.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Elena IvanovaDepartment of Ophthalmology, Brain and Mind Research Institute, Weill Cornell Medical College, Burke Medical Research Institute, White Plains, NY, 10605, USA.
Christopher W YeeDepartment of Ophthalmology, Brain and Mind Research Institute, Weill Cornell Medical College, Burke Medical Research Institute, White Plains, NY, 10605, USA.
Botir T SagdullaevDepartment of Ophthalmology, Brain and Mind Research Institute, Weill Cornell Medical College, Burke Medical Research Institute, White Plains, NY, 10605, USA. bos2005@med.cornell.edu.ORCID http://orcid.org/0000-0002-0611-1479
Cornell University · US

Funding

Vascular control in diabetic retinopathyR01EY026576 · NEI · WINIFRED MASTERSON BURKE MED RES INST · PI SAGDULLAEV, BOTIR T. · 2016 to 2020
$2.9M
Retinal neural processing during retinal degenerative diseasesR01EY020535 · NEI · WINIFRED MASTERSON BURKE MED RES INST · PI SAGDULLAEV, BOTIR T. · 2010 to 2014
$2.4M
NEI NIH HHS R01 EY020535NEI NIH HHS R01 EY026576
6 · The paper itself

Abstract

Optogenetic techniques are a powerful tool for determining the role of individual functional components within complex neural circuits. By genetically targeting specific cell types, neural mechanisms can be actively manipulated to gain a better understanding of their origin and function, both in health and disease. The potential of optogenetics is not limited to answering biological questions, as it is also a promising therapeutic approach for neurological diseases. An important prerequisite for this approach is to have an identified target with a uniquely defined role within a given neural circuit. Here, we examine the retinal neurovascular unit, a circuit that incorporates neurons and vascular cells to control blood flow in the retina. We highlight the role of a specific cell type, the cholinergic amacrine cell, in modulating vascular cells, and demonstrate how this can be targeted and controlled with optogenetics. A better understanding of these mechanisms will not only extend our understanding of neurovascular interactions in the brain, but ultimately may also provide new targets to treat vision loss in a variety of retinal diseases.

Indexed as

OptogeneticsAnimalsHumansNervous System DiseasesNeural PathwaysAcetylcholineAmacrine cellNeurovascular unitOptogeneticsPericyte

Identifiers

PMID26758692
PMCPMC4824015
OpenAlexW2233627556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.